Loading...
Market
Outcome of Agios' next Phase 3 trial by June 30, 2025?
4
Resolution / Starting Odds
Positive • 33%
Negative • 33%
Neutral • 33%
Company press releases and clinical trial results publications
Story
Agios' Mitapivat Achieves Positive Phase 3 Results for Thalassemia, 30.4% Response, Stock Up 20%
Jun 3, 2024, 11:24 AM
Agios Pharmaceuticals announced on Monday that its drug Mitapivat achieved positive results in a Phase 3 study for treating transfusion-dependent alpha- or beta-thalassemia in adults. The study, named ENERGIZE-T, met its primary endpoint and all key secondary endpoints. The response rate for Mitapivat was 30.4% compared to 12.6% for the placebo, showing significant reduction in the need for blood transfusions. Following the announcement, Agios' stock price surged by 20%, reaching a 2.5-year high.
View original story
Similar markets
FDA approval • 25%
EMA approval • 25%
Both approvals • 25%
No approvals • 25%
Phase 4 trial initiated • 33%
Additional Phase 3 trial initiated • 33%
No further trials announced • 33%
Positive results • 33%
Neutral results • 34%
Negative results • 33%
Phase 4 trial • 25%
Approval in additional markets • 25%
Development of new formulations • 25%
Strategic partnership or collaboration • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Under 5 • 25%
5 to 10 • 25%
11 to 20 • 25%
More than 20 • 25%